In conclusion, our findings shed light on EWS–WT1–associated genetic vulnerabilities in DSRCT and provide a rationale for evaluating PARPi in combination with ATRi in this deadly disease. The gene discussed is WT1; the disease is desmoplastic small round cell tumor.